

Psychiatry Drug Alerts 2018 Self-Assessment Module 7: Peer Comparison

You recently participated in an ABPN-approved Self-Assessment activity relevant to your specialty and/or subspecialty. This peer comparison report provides you with feedback on your performance, relative to your peers, on the test module. In order to recognize your current knowledge base and to identify specific topics where further study may be needed, please review your answers to the following questions and compare them with those of your peers.

1) The FDA approved a new injectable aripiprazole formulation (*Aristada Initio*) to be used in combination with a single dose of oral aripiprazole (*Abilify*) plus any available dose of long-acting injectable aripiprazole lauroxil (*Aristada*) on day 1 to initiate treatment for schizophrenia. The new regimen produces relevant aripiprazole levels within _____ days of initiation.

4	100.00 %
14	0.00 %
21	0.00 %

2) In a long-term follow-up comparing outcomes in children of breastfeeding women who were and were not taking psychotropic medications, exposed children demonstrated:

Normal growth	100.00 %
Slower growth	0.00 %
Faster weight gain	0.00 %
Reduced head circumference	0.00 %

3) Developmental milestones were all within the normal range in exposed children, although some occurred a few days to weeks later than in controls.

True	100.00 %
False	0.00 %

4) In a population-based case-control study in patients with schizophrenia, risk of chronic kidney disease (CKD) was significantly increased in the patients taking.

No antipsychotic	0.00 %
Second-generation antipsychotics (alone or in combination)	100.00 %
First-generation agents only	0.00 %
None of the above	0.00 %

5) In this study, the relationship between second-generation antipsychotics and CKD _____ dose related.

Was	7.14 %
Was not	92.86 %

6) In a randomized trial comparing adjunctive levothyroxine, T4, and placebo in patients with refractory rapid cycling bipolar disorder, patients taking levothyroxine spent significantly _____, compared with the pre-treatment period.

Less time in a depressed state	0.00 %
Less time in a mixed state	7.14 %
More time euthymic	0.00 %
All of the above	92.86 %

7) In this study, between-group comparisons showed that favorable mood changes in patients who received levothyroxine were significantly superior to placebo for time spent:

In a depressed state	0.00 %
In a mixed state and a depressed state	14.29 %
Euthymic	0.00 %
Euthymic and in a mixed state	85.71 %

8) In a population-based study, exposure to anticholinergic drugs prescribed as _____ agents was associated with an increase in the incidence of dementia.

Urological	0.00 %
Antiparkinsonian	0.00 %
Antidepressant	0.00 %
All of the above	100.00 %

9) In this study, a dose-response relationship was evident for drugs with established and clinically relevant anticholinergic effects.

True	100.00 %
False	0.00 %

10) The investigational drug roluperidone (MIN-101) has been shown to improve negative symptoms of schizophrenia. Results of a post-hoc analysis of a manufacturer-sponsored trial suggest possible secondary benefits on:

Positive symptoms	0.00 %
Cognitive performance	100.00 %
Attention	0.00 %
All of the above	0.00 %

11) Roluperidone has specific affinities for the sigma-2, 5-HT_{2a} and alpha₁-adrenergic receptors and lacks the anticholinergic and antihistaminergic activity associated with other medications that can worsen cognitive function in patients with schizophrenia.

True	100.00 %
False	0.00 %

12) According to a review and meta-analysis of vesicular monoamine transporter-2 (VMAT-2) inhibitors for treatment of tardive dyskinesia, robust evidence supports:

Tetrabenazine and valbenazine	0.00 %
Deutetrabenazine and valbenazine	100.00 %
Tetrabenazine and deutetrabenazine	0.00 %
None of the above	0.00 %

13) Due to its short half-life of about 5 hours, tetrabenazine has large variations in drug levels that have off-target effects such as sedation, acute motor syndromes, and _____; deutetrabenazine and valbenazine appear to lack these effects.

Depression and suicidality	100.00 %
Orthostatic hypotension	0.00 %
Dementia	0.00 %